Krishna Institu.

INR
811.00
3.15 (0.39%)
BSENSE

Aug 07, 03:30 PM

BSE+NSE Vol: 26.91 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

26.91 lacs (110.22%) Volume

Shareholding (Jun 2026)

FII

14.44%

Held by 168 FIIs

DII

34.60%

Held by 59 DIIs

Promoter

32.50%

Why is Krishna Institute of Medical Sciences Ltd falling/rising?

08-Aug-2026

As of 07-Aug, the stock price of Krishna Institute of Medical Sciences Ltd is rising to 811.00, driven by consistent performance, strong investor interest, and high institutional holdings. It has outperformed the Sensex with a year-to-date return of 33.59% and shows a strong upward trend above its moving averages.

As of 07-Aug, the stock price of Krishna Institute of Medical Sciences Ltd is rising, currently at 811.00, reflecting a change of 3.15 (0.39%) upward. This increase can be attributed to several factors. The stock has shown consistent performance, gaining for the last three days with a total return of 2.19% during this period. Additionally, it has outperformed the benchmark Sensex in both the short term and long term, with a year-to-date return of 33.59% compared to the Sensex's decline of 7.89%.<BR><BR>The stock is also trading above its moving averages across various time frames, indicating a strong upward trend. Furthermore, there has been a notable increase in investor participation, with delivery volume rising by 34.04% against the five-day average, suggesting growing interest among investors. High institutional holdings at 49.03%, which have increased by 1.96% over the previous quarter, further support the stock's positive outlook, as institutional investors typically have more resources to analyze company fundamentals.<BR><BR>Overall, these factors contribute to the stock's rising price, reflecting strong market confidence in Krishna Institute of Medical Sciences Ltd.

View full answer

Are Krishna Institute of Medical Sciences Ltd latest results good or bad?

04-Aug-2026

Krishna Institute of Medical Sciences Ltd's latest results show strong revenue growth of 35.33% year-on-year, reaching ₹1,179.50 crores, but net profit fell 47.20% to ₹41.50 crores, raising concerns about profitability and increased debt levels. Overall, while revenue growth is positive, the decline in profit and rising financial risk suggest mixed results.

The latest results for Krishna Institute of Medical Sciences Ltd present a mixed picture. On one hand, the company achieved impressive revenue growth, with net sales increasing by 35.33% year-on-year to ₹1,179.50 crores, marking the highest quarterly revenue in its history. This growth indicates strong demand and operational momentum across its hospital network.<BR><BR>However, the profitability metrics have raised concerns. The net profit for the quarter fell significantly by 47.20% year-on-year to ₹41.50 crores, and the operating margin contracted to 18.94%, down from 22.10% a year earlier. This margin compression is attributed to rising employee costs and increased interest expenses, which surged by 155.83% year-on-year. The company's debt levels have also escalated, leading to a debt-to-equity ratio of 1.89, indicating heightened financial risk.<BR><BR>Overall, while the revenue growth is a positive sign, the sharp decline in profitability and increased debt levels suggest that the results are not entirely favorable. Investors may need to weigh these factors carefully when considering the company's financial health and future prospects.

View full answer

Should I buy, sell or hold Krishna Institute of Medical Sciences Ltd?

04-Aug-2026

What does Krishna Institu. do?

11-Jun-2026

Krishna Institute of Medical Sciences Ltd is a small-cap company in the hospital industry, incorporated in 1973, with recent quarterly net sales of ₹1,075 Cr and net profit of ₹42 Cr as of March 2026. Key financial metrics include a market cap of ₹31,027 Cr, P/E ratio of 123.00, and a debt-equity ratio of 1.85.

Overview:<BR>Krishna Institute of Medical Sciences Ltd operates in the hospital industry and is categorized as a small-cap company.<BR><BR>History:<BR>The company was incorporated in 1973 as 'Jagjit Singh and Sons Private Limited' and later changed its name to 'Krishna Institute of Medical Sciences Private Limited' in 2004. Following its conversion to a public limited company, it adopted the name 'Krishna Institute of Medical Sciences Limited' on January 29, 2004. The most recent quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 1,075 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 42 Cr (Quarterly Results - Mar 2026)<BR>- Market Cap: INR 31,027 Cr (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: 123.00<BR>- Industry P/E: 60<BR>- Dividend Yield: 0.00%<BR>- Debt-Equity: 1.85<BR>- Return on Equity: 11.03%<BR>- Price to Book: 13.94<BR><BR>Contact Details:<BR>Details: No Company Details Available<BR>Registrar Address: Not available.

View full answer

How big is Krishna Institu.?

11-Jun-2026

As of 10th June, Krishna Institute of Medical Sciences Ltd has a market capitalization of 31,027.00 Cr, with recent Net Sales of 3,904.60 Cr and a Net Profit of 241.40 Cr. Shareholder's Funds were 2,137.80 Cr, and Total Assets amounted to 5,676.10 Cr for the latest annual period ending March 2025.

As of 10th June, Krishna Institute of Medical Sciences Ltd has a market capitalization of 31,027.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 3,904.60 Cr and a Net Profit of 241.40 Cr.<BR><BR>For the latest annual period ending March 2025, the Shareholder's Funds were 2,137.80 Cr, and the Total Assets amounted to 5,676.10 Cr.

View full answer

Who are in the management team of Krishna Institu.?

11-Jun-2026

The management team of Krishna Institu includes Bhaskara Rao Bollineni (Chairman & Managing Director), Abhinay Bollineni (Executive Director & CEO), and several independent directors, bringing diverse expertise to the company.

The management team of Krishna Institu includes the following key members:<BR><BR>1. **Bhaskara Rao Bollineni** - Chairman & Managing Director<BR>2. **Abhinay Bollineni** - Executive Director & CEO<BR>3. **Dandamudi Anitha** - Whole-Time Director & Executive Director<BR>4. **Rajeswara Rao Gandu** - Independent Director<BR>5. **Saumen Chakraborty** - Independent Director<BR>6. **Pankaj Vaish** - Independent Director<BR>7. **Ratna Kishore Kaza** - Independent Director<BR>8. **J V Ramudu** - Independent Director<BR>9. **Y Prameela Rani** - Independent Director<BR>10. **Shantanu Rastogi** - Non-Executive Director<BR>11. **Adwik Bollineni** - Additional Director<BR><BR>This team brings a diverse range of expertise and leadership to the company.

View full answer

Who are the peers of the Krishna Institu.?

11-Jun-2026

Peers of Krishna Institu. include Max Healthcare, Fortis Health, Aster DM Health, Narayana Hrudaya, Global Health, Dr Agarwal's Health, Rainbow Children’s Hospital, and Jupiter Life Line. Krishna Institu. has good management risk and a 1-year return of 15.42%, higher than Max Healthcare but lower than Aster DM Health's 42.08%.

Peers: The peers of Krishna Institu. are Max Healthcare, Fortis Health., Aster DM Health., Narayana Hrudaya, Global Health, Dr Agarwal's Hea, Rainbow Child., Health.Global, Jupiter Life Lin.<BR><BR>Quality Snapshot: Excellent management risk is observed at Max Healthcare and Narayana Hrudaya, while Good management risk is found at Aster DM Health., Global Health, Krishna Institu., Rainbow Child., and Jupiter Life Lin. Average management risk is present at Fortis Health. and Dr Agarwal's Hea. For growth, Excellent growth is noted at Max Healthcare and Narayana Hrudaya, while Good growth is seen at Dr Agarwal's Hea. Below Average growth is reported for Aster DM Health., Global Health, Krishna Institu., Rainbow Child., and Jupiter Life Lin. Excellent capital structure is found at Max Healthcare and Global Health, Good capital structure is present at Fortis Health., Krishna Institu., Dr Agarwal's Hea., Rainbow Child., and Jupiter Life Lin, while Average capital structure is noted at Aster DM Health.<BR><BR>Return Snapshot: Aster DM Health. has the highest 1-year return at 42.08%, while Max Healthcare has the lowest at -14.68%. Krishna Institu.'s 1-year return is 15.42%, which is higher than Max Healthcare but lower than Aster DM Health. Additionally, the peers with negative six-month returns are Max Healthcare, Dr Agarwal's Hea., and Rainbow Child.

View full answer

When is the next results date for Krishna Institute of Medical Sciences Ltd?

07-May-2026

The next results date for Krishna Institute of Medical Sciences Ltd is 15 May 2026.

The next results date for Krishna Institute of Medical Sciences Ltd is scheduled for 15 May 2026.

View full answer

Is Krishna Institu. technically bullish or bearish?

02-Dec-2025

As of December 1, 2025, the trend is mildly bullish due to daily moving averages, but caution is advised as weekly MACD and KST are bearish, despite a bullish weekly RSI and mixed signals from Bollinger Bands.

As of 1 December 2025, the technical trend has changed from sideways to mildly bullish. The current stance is mildly bullish, driven by the daily moving averages indicating bullish momentum. However, the weekly MACD and KST are both mildly bearish, which suggests some caution. The weekly RSI is bullish, supporting the positive outlook, while the Bollinger Bands show a mixed signal with a bullish monthly perspective. Overall, the strength of the bullish sentiment is tempered by the bearish signals in the weekly indicators.

View full answer

Is Krishna Institu. overvalued or undervalued?

27-Nov-2025

As of November 26, 2025, Krishna Institute is considered very expensive with a PE ratio of 83.68, significantly higher than peers like Apollo Hospitals and Max Healthcare, indicating it is overvalued despite a 14.51% return over the past year compared to the Sensex's 7.01%.

As of 26 November 2025, the valuation grade for Krishna Institute has moved from expensive to very expensive. This indicates that the company is currently overvalued. Key ratios highlight this situation, with a PE ratio of 83.68, an EV to EBITDA of 38.97, and a Price to Book Value of 12.07. <BR><BR>In comparison to peers, Krishna Institute's valuation is notably higher than that of Apollo Hospitals, which has a PE ratio of 63.6 and an EV to EBITDA of 33.45, indicating that Krishna is trading at a significant premium. Additionally, Max Healthcare, another peer, has a PE ratio of 80.02, further emphasizing the elevated valuation of Krishna Institute. While the company has outperformed the Sensex over the past year with a return of 14.51% compared to the Sensex's 7.01%, the current valuation suggests caution for potential investors.

View full answer

How has been the historical performance of Krishna Institu.?

24-Nov-2025

Krishna Institu has demonstrated consistent growth from March 2020 to March 2025, with net sales increasing from INR 1,122.65 crore to INR 3,035.00 crore, and profit after tax rising from INR 115.07 crore to INR 414.50 crore. The company's total assets and cash flow from operating activities also significantly improved during this period.

Answer:<BR>The historical performance of Krishna Institu shows a consistent growth trajectory in net sales and profitability over the years.<BR><BR>Breakdown:<BR>Krishna Institu's net sales have increased significantly from INR 1,122.65 crore in March 2020 to INR 3,035.00 crore in March 2025, demonstrating a strong upward trend. The total operating income followed a similar pattern, reaching INR 3,035.00 crore in March 2025, up from INR 1,122.65 crore in March 2020. The company's operating profit (PBDIT) also saw substantial growth, rising from INR 251.08 crore in March 2020 to INR 814.60 crore in March 2025. Profit before tax increased from INR 140.53 crore in March 2020 to INR 557.90 crore in March 2025, while profit after tax rose from INR 115.07 crore to INR 414.50 crore in the same period. The company's total assets grew from INR 1,194.47 crore in March 2020 to INR 5,676.10 crore in March 2025, indicating a robust expansion in its asset base. Total liabilities also increased, from INR 1,194.47 crore to INR 5,676.10 crore, reflecting the company's growing financial commitments. Cash flow from operating activities improved from INR 201.00 crore in March 2020 to INR 581.00 crore in March 2025, while net cash inflow turned positive at INR 9.00 crore in March 2025, compared to a net outflow in previous years. Overall, Krishna Institu has shown strong growth in sales, profits, and asset accumulation over the past five years.

View full answer

Who are the top shareholders of the Krishna Institu.?

17-Jul-2025

The top shareholders of Krishna Institu include promoter Bhaskara Rao Bollineni with 26.27%, mutual funds at 25.35%, foreign institutional investors at 15.45%, and the SBI Small Cap Fund as the largest public shareholder with 6.31%. Individual investors collectively hold 11.24% of the shares.

The top shareholders of Krishna Institu include the promoters, who hold a majority stake in the company. The promoter with the highest holding is Bhaskara Rao Bollineni, with a significant 26.27%. Additionally, mutual funds hold 25.35% of the shares through 24 different schemes, while foreign institutional investors (FIIs) account for 15.45% with 171 FIIs involved. The highest public shareholder is the SBI Small Cap Fund, which holds 6.31%. Individual investors collectively hold 11.24% of the shares.

View full answer

Has Krishna Institu. declared dividend?

06-Jun-2025

No Dividend History Available

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

High Management Efficiency with a high ROCE of 17.88%

 
2

Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 11.75

 
3

Poor long term growth as Operating profit has grown by an annual rate 4.18% of over the last 5 years

 
4

With a fall in Net Profit of -31.23%, the company declared Very Negative results in Jun 26

5

With ROCE of 8.1, it has a Very Expensive valuation with a 6 Enterprise value to Capital Employed

6

High Institutional Holdings at 49.03%

stock-summaryMojo Parameters

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

stock-summary
Industry

Hospital

stock-summary
Market cap

INR 33,955 Cr (Small Cap)

stock-summary
P/E

162.00

stock-summary
Industry P/E

69

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

1.85

stock-summary
Return on Equity

11.03%

stock-summary
Price to Book

15.10

Revenue and Profits:
Net Sales:
1,180 Cr
(Quarterly Results - Jun 2026)
Net Profit:
42 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
14.62%
0%
14.62%
6 Months
36.31%
0%
36.31%
1 Year
9.06%
0%
9.06%
2 Years
89.32%
0%
89.32%
3 Years
118.6%
0%
118.6%
4 Years
228.42%
0%
228.42%
5 Years
230.13%
0%
230.13%

Krishna Institu. for the last several years.

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions

News

Krishna Institute of Medical Sciences Ltd Gains 0.81%: 3 Key Factors Driving the Week

Announcements stock-summary

Business Responsibility and Sustainability Reporting (BRSR)

05-Aug-2026 | Source : BSE

BRSR for the FY 2025-26

Reg. 34 (1) Annual Report.

05-Aug-2026 | Source : BSE

24th Annual Report for the FY 2025-26

24Th Annual General Meeting Of The Company Scheduled To Be Held On 27Th August 2026

05-Aug-2026 | Source : BSE

24th Annual General Meeting Scheduled to be held on 27th August 2026

Corporate Actions stock-summary

stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

No Dividend history available

stock-summary
SPLITS

Krishna Institute of Medical Sciences Ltd has announced 2:10 stock split, ex-date: 13 Sep 24

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available

stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
21.33%
EBIT Growth (5y)
4.18%
EBIT to Interest (avg)
11.75
Debt to EBITDA (avg)
2.15
Net Debt to Equity (avg)
1.85
Sales to Capital Employed (avg)
0.83
Tax Ratio
29.74%
Dividend Payout Ratio
0
Pledged Shares
10.26%
Institutional Holding
49.03%
ROCE (avg)
20.10%
ROE (avg)
17.81%

Valuation key factors

Factor
Value
P/E Ratio
162
Industry P/E
69
Price to Book Value
15.16
EV to EBIT
76.12
EV to EBITDA
45.90
EV to Capital Employed
5.96
EV to Sales
9.07
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
8.09%
ROE (Latest)
11.03%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Bullish
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2026stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

10.2572

Mutual Funds

Held by 33 Schemes (28.7%)

FIIs

Held by 168 FIIs (14.44%)

Promoter with highest holding

Bhaskara Rao Bollineni (25.02%)

Highest Public shareholder

Sbi Small Cap Fund (5.17%)

Individual Investors Holdings

11.22%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2026 is 9.76% vs 7.71% in Mar 2026",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2026 is -2.35% vs -20.41% in Mar 2026",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'26",
        "Mar'26",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,179.50",
          "val2": "1,074.60",
          "chgp": "9.76%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "223.40",
          "val2": "206.50",
          "chgp": "8.18%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "83.40",
          "val2": "68.10",
          "chgp": "22.47%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-10.90",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "41.50",
          "val2": "42.50",
          "chgp": "-2.35%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "18.94%",
          "val2": "19.22%",
          "chgp": "-0.28%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Consolidated) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2025 is 25.01% vs 16.46% in Sep 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": " Growth in half year ended Sep 2025 is -25.00% vs 12.25% in Sep 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,832.30",
          "val2": "1,465.70",
          "chgp": "25.01%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "396.60",
          "val2": "397.50",
          "chgp": "-0.23%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "77.60",
          "val2": "37.80",
          "chgp": "105.29%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "145.50",
          "val2": "194.00",
          "chgp": "-25.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "21.64%",
          "val2": "27.12%",
          "chgp": "-5.48%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Dec 2025 is 26.45% vs 20.05% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in nine months ended Dec 2025 is -29.64% vs 15.54% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,830.00",
          "val2": "2,238.10",
          "chgp": "26.45%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "595.50",
          "val2": "584.70",
          "chgp": "1.85%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "134.40",
          "val2": "63.50",
          "chgp": "111.65%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "198.90",
          "val2": "282.70",
          "chgp": "-29.64%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "21.04%",
          "val2": "26.12%",
          "chgp": "-5.08%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'26",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2026 is 28.65% vs 21.49% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2026 is -37.22% vs 24.03% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "3,904.60",
          "val2": "3,035.00",
          "chgp": "28.65%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "802.00",
          "val2": "782.70",
          "chgp": "2.47%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "202.50",
          "val2": "90.20",
          "chgp": "124.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-11.20",
          "val2": "10.80",
          "chgp": "-203.70%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "241.40",
          "val2": "384.50",
          "chgp": "-37.22%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "20.54%",
          "val2": "25.79%",
          "chgp": "-5.25%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQstock-summary

Jun'26
Mar'26
Change(%)
Net Sales
1,179.50
1,074.60
9.76%
Operating Profit (PBDIT) excl Other Income
223.40
206.50
8.18%
Interest
83.40
68.10
22.47%
Exceptional Items
0.00
-10.90
100.00%
Consolidate Net Profit
41.50
42.50
-2.35%
Operating Profit Margin (Excl OI)
18.94%
19.22%
-0.28%
Values in Rs Cr.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2026 is 9.76% vs 7.71% in Mar 2026

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2026 is -2.35% vs -20.41% in Mar 2026

Half Yearly Results Snapshot (Consolidated) - Sep'25stock-summary

Sep'25
Sep'24
Change(%)
Net Sales
1,832.30
1,465.70
25.01%
Operating Profit (PBDIT) excl Other Income
396.60
397.50
-0.23%
Interest
77.60
37.80
105.29%
Exceptional Items
0.00
0.00
Consolidate Net Profit
145.50
194.00
-25.00%
Operating Profit Margin (Excl OI)
21.64%
27.12%
-5.48%
Values in Rs Cr.
Direction Arrows
Net Sales

Growth in half year ended Sep 2025 is 25.01% vs 16.46% in Sep 2024

Direction Arrows
Consolidated Net Profit

Growth in half year ended Sep 2025 is -25.00% vs 12.25% in Sep 2024

Nine Monthly Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
2,830.00
2,238.10
26.45%
Operating Profit (PBDIT) excl Other Income
595.50
584.70
1.85%
Interest
134.40
63.50
111.65%
Exceptional Items
0.00
0.00
Consolidate Net Profit
198.90
282.70
-29.64%
Operating Profit Margin (Excl OI)
21.04%
26.12%
-5.08%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in nine months ended Dec 2025 is 26.45% vs 20.05% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in nine months ended Dec 2025 is -29.64% vs 15.54% in Dec 2024

Annual Results Snapshot (Consolidated) - Mar'26stock-summary

Mar'26
Mar'25
Change(%)
Net Sales
3,904.60
3,035.00
28.65%
Operating Profit (PBDIT) excl Other Income
802.00
782.70
2.47%
Interest
202.50
90.20
124.50%
Exceptional Items
-11.20
10.80
-203.70%
Consolidate Net Profit
241.40
384.50
-37.22%
Operating Profit Margin (Excl OI)
20.54%
25.79%
-5.25%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2026 is 28.65% vs 21.49% in Mar 2025

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2026 is -37.22% vs 24.03% in Mar 2025

stock-summaryCompany CV
About Krishna Institute of Medical Sciences Ltd stock-summary
stock-summary
Krishna Institute of Medical Sciences Ltd
Small Cap
Hospital
Krishna Institute of Medical Sciences Limited (KIMS) was erstwhile incorporated as `Jagjit Singh and Sons Private Limited', a Private Limited Company on July 26, 1973 in Mumbai. Subsequently, the name of the Company changed to `Krishna Institute of Medical Sciences Private Limited' on January 2, 2004 and further upon its conversion to a Public Limited Company, the name was changed to `Krishna Institute of Medical Sciences Limited' on January 29, 2004.
Company Coordinates stock-summary
Icon
No Company Details Available